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Abstract Genetic defects in amino acid metabolism are
major causes of newborn diseases that often lead to
abnormal development and function of the central nervous
system. Their direct impact on cardiac development and
function has rarely been investigated. Recently, the authors
have established that a mitochondrial targeted 2C-type ser/
thr protein phosphatase, PP2Cm, is the endogenous phos-
phatase of the branched-chain alpha keto acid-dehydroge-
nase complex (BCKD) and functions as a key regulator in
branched-chain amino acid catabolism and homeostasis.
Genetic inactivation of PP2Cm in mice leads to signiﬁcant
elevation in plasma concentrations of branched-chain
amino acids and branched-chain keto acids at levels similar
to those associated with intermediate mild forms of maple
syrup urine disease. In addition to neuronal tissues, PP2Cm
is highly expressed in cardiac muscle, and its expression is
diminished in a heart under pathologic stresses. Whereas
phenotypic features of heart failure are seen in PP2Cm-
deﬁcient zebra ﬁsh embryos, cardiac function in PP2Cm-
null mice is compromised at a young age and deteriorates
faster by mechanical overload. These observations suggest
that the catabolism of branched-chain amino acids also has
physiologic signiﬁcance in maintaining normal cardiac
function. Defects in PP2Cm-mediated catabolism of bran-
ched-chain amino acids can be a potential novel mecha-
nism not only for maple syrup urine disease but also for
congenital heart diseases and heart failure.
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Amino Acid Metabolism and Genetic Disorders
Amino acids are key nutrient molecules essential for cell
growth, survival, and normal function. In addition to pro-
viding building blocks for protein synthesis, many amino
acids are an essential ingredient for biosynthesis of other
molecules as the sources of nitrogen and carbon [8]. Some
amino acids, including branched-chain amino acids, also
have been shown to possess a potent signaling function to
regulate global growth and metabolism [2, 13, 14, 17, 18,
22, 23]. Therefore, the impact of amino acid metabolism on
embryonic development and human congenital diseases
has long been recognized.
Maple syrup urine disease, one of the most common
genetic disorders caused by defects in amino acid metabo-
lism, is a target of mandatory newborn screening in most of
the United States and throughout the world [5, 10, 20]. The
clinicalmanifestationsofclassicalmaplesyrupurinedisease
are mostly neuropathologic, including seizure and mental
retardation[7].However,recent studiesfromanimalmodels
of maple syrup urine disease raise concerns about the
potential adverse impact of branched-chain amino acid
metabolic defects on cardiac development and function.
Theseconcernsarethefocusofthediscussioninthisreview.
Catabolism of Branched-Chain Amino Acids
Branched-chain amino acids (BCAAs) including leucine,
isoleucine, and valine are essential amino acids that must
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dant presence in protein peptides as key hydrophobic
building blocks, BCAAs also serve as signiﬁcant sources
for biosynthesis of sterol, keto bodies, and glucose [3].
Among the BCAAs, particularly leucine has potent sig-
naling activity to promote protein synthesis, cellular
metabolism, and cell growth in a mammalian target of
rapamycin (mTOR)-dependent manner [4, 15, 19].
Although BCAAs are necessary for normal growth and
function at cellular and organism levels, an excess amount
of free BCAAs also can be pathologic. A high plasma
level of BCAAs is the benchmark and cause of maple syrup
urine disease, a potentially life-threatening disorder
affecting 1 of 180,000 newborn babies on the average in
the general population, with a much higher prevalence
among certain Amish, Mennonite, and Jewish communities
[5, 20].
Because BCAAs are essential amino acids with no bio-
synthesis pathways in animal cells, their homeostasis is
determined largely by catabolic activities in a number of
organs, particularly the liver [9]. The ﬁrst step in the catab-
olism of BCAAs is carried out in brain, muscle, and many
nonhepatic tissues by the branched-chain aminotransferase
(BCAT) to convert BCAAs into branched-chain alpha keto
acids (BCKAs) [9]. The BCKAs are decarboxylated by the
branched-chain alpha keto acid dehydrogenase (BCKD)
complex in the liver as well as other tissues and eventually
degradedintoacetyl-coenzymeA(CoA)orsuccinyl-CoAto
fuel the TCA cycle. As BCKD mediates this rate-limiting
step in BCAA catabolism, its activity dictates the steady-
state levels of BCAA and BCKA. It thus is a target of mul-
tiple regulatory mechanisms, including cyclic adenosine
monophosphate (cAMP)-mediated induction of RNA tran-
scription and phosphorylation-mediated inhibition/activa-
tion of its enzymatic activity.
The BCKD complex is genetically linked with the
pyruvate dehydrogenase complex (PDH) because they
share extensive homology in their subunit composition and
regulation. Like PDH, BCKD holoenzyme contains 24
copies of catalytic subunits E2/E3 and an equal number of
regulatory subunits E1a and E1b. At low BCAA levels,
E1a is hyperphosphorylated by BCKD kinase, leading to
lower BCKD activity and reduced loss of BCAA. At a high
BCAA level, E1a is dephosphorylated by BCKD phos-
phatase, leading to induced BCKD activity and the removal
of excess BCAA. Therefore, BCKD phosphorylation/
dephosphorylation is critical to BCAA homeostasis [9].
Molecular Identiﬁcation of BCKD Phosphatase
Based on the importance of BCKD phosphorylation in its
regulation, BCKD phosphatase has been well established
as a key regulator in BCAA catabolism. However, its
molecular identity has remained elusive for decades.
Recently, through genome scanning, we discovered a
mitochondrial targeted 2C-type ser/thr protein phosphatase
that we named PP2C in mitochondria (PP2Cm) [11].
Through extensive proteomic and biochemical analysis,
we established that PP2Cm is the missing BCKD phos-
phatase responsible for BCAA-induced dephosphorylation
and activation of BCKD activity [12]. This conclusion is
based on the following lines of evidence: (1) BCKD sub-
units, including E2 and E1a, are speciﬁcally associated
with PP2Cm in vitro and in vivo; (2) PP2Cm expression
effectively dephosphorylates E1a Ser-293 phosphorylation,
a key residue in BCKD enzymatic regulation; (3) PP2Cm-
deﬁcient cells have elevated basal E1a phosphorylation,
which remains high at BCKA treatment; (4) PP2Cm-deﬁ-
cient mice have a signiﬁcantly higher plasma level of
BCAA and BCKA with impaired BCAA clearance after a
high dose of BCAA ingestion; and (5) PP2Cm-deﬁcient
newborn mice have signiﬁcantly higher mortality under a
high-protein diet challenge.
All these data establish that PP2Cm is the endogenous
BCKD phosphatase with an essential function in BCAA
catabolism. The analysis with PP2Cm KO mice indicates
that a defect in PP2Cm is a potential novel mechanism for
the intermediate/inducible forms of maple syrup urine
disease.
PP2Cm in Cardiac Regulation
The discovery of PP2Cm as the BCKD phosphatase and a
key regulator in BCAA metabolism as well as the estab-
lishment of PP2Cm-deﬁcient zebra ﬁsh and mouse models
offers an opportunity to investigate the impact of BCAA
regulation in intact animals. In both zebra ﬁsh embryos and
adult mice, PP2Cm is highly expressed in both cardiac
muscle and the central nervous system (Figs. 1, 2). Its
expression in the heart is dynamically regulated by stress, as
measured by both mRNA and protein levels, with signiﬁ-
cantly reduced levels in hypertrophic and failing hearts [11].
It is not clear whether loss of PP2Cm is a contributing
factor to cardiac pathology or simply a phenomenon asso-
ciated with the diseased hearts. To investigate this question,
we analyzed the cardiac performance in PP2Cm-deﬁcient
zebra ﬁsh and mice. Using morpholingoes speciﬁcally tar-
geted to zPP2Cm translation initiation codon (ATG-MO),
we demonstrated that. PP2Cm-deﬁcient ﬁsh embryos dis-
playedadose-dependentlossofcardiaccontractilityandthat
most of them did not survive beyond the early embryonic
stage [11]. Accelerated heart failure developed in PP2Cm-
deﬁcient mice after mechanical overload induced by trans-
aortic constriction (Fig. 3).
306 Pediatr Cardiol (2011) 32:305–310
123These evidences suggest that loss of PP2Cm is not a
mere consequence but rather a signiﬁcant contributor to the
pathogenesis of heart failure. These studies for the ﬁrst
time implicated BCAA catabolism also as an important
aspect of cardiac pathophysiology and showed that defects
in BCAA homeostasis can have a signiﬁcant adverse
impact on cardiac function and disease progression.
The underlying mechanisms for the clinical manifesta-
tions of maple syrup urine disease still are not well
established, and the adverse impact on glutamine transport
and the induction of reactive-oxygen species (ROS) have
been implicated [1, 6, 24]. In our own studies with cardiac
tissue or cultured cardiomyocytes, we also explored a
number of these possible mechanisms.
1. We examined the cytotoxic effect of the accumulated
BCAA/BCKA on cadiomyocyte survival, demonstrating
that PP2Cm-deﬁcient mice have a signiﬁcantly elevated
ROS level and are more susceptible to calcium-induced
permeability transition pore opening in mitochondria
[11]. Whether and how this effect is caused by accumu-
latedBCAAorBCKAremainstobeinvestigatedfurther.
However,aclearimplicationoftheobservedcytotoxicity
is more cell death. Indeed, we observed that PP2Cm
deﬁciency can lead to more apoptotic cell death in both
developing embryos and cultured myocytes.
2. Metabolic effects of accumulated BCAA/BCKA can
be pathologic in the heart. It is known that BCAA/
BCKA can inhibit pyruvate and fatty acid transport
and utilization [16, 19]. Because cardiac tissue has a
constant high demand for pyruvate and fatty acid as its
main fuel source, chronically elevated BCAA/BCKA
can potentially block normal bioenergenic homeostasis
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Fig. 1 Expression pattern of PP2C in mitochondria (PP2Cm) of
developing zebra ﬁsh embryos. a–f In situ hybridization signal of
fPP2Cm mRNA in developing zebra ﬁsh embryos at a speciﬁc stage
as indicated (hpf: hour postfertilization). g Transgene construct of
fPP2Cm promoter driving GFP expression. h GFP signal observed
under ultraviolet illumination in transgenic zebraﬁsh at 72 hpf stage
under different magniﬁcations. Arrows indicate heart tube
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accelerated heart failure under increased mechanical
load or aging. Although we observed signiﬁcant
changes in a number of metabolic genes in PP2Cm-
deﬁcient hearts (Lu et al., unpublished results), a direct
analysis of cardiac metabolic status and energy
consumption is needed to support this hypothesis.
3. Our ﬁndings showed that PP2Cm mediated direct
modiﬁcation of mitochondrial function in cellular
bioenergenics and survival. Although BCKD is the
only substrate identiﬁed for PP2Cm to date, it is
possible that other uncharacterized substrates in mito-
chondria contribute to PP2Cm-mediated signaling.
This is supported by our observation that the isolated
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Line Scanning
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AB Fig. 2 Loss of fPP2Cm
expression leads to heart failure
in zebra ﬁsh embryo. a Video
frames of cmlc-GFP transgenic
ﬁsh embryo recorded under
ultraviolet illumination after
treatment with different
concentrations of PP2Cm
morpholigo. b M-mode image
of zebra ﬁsh hearts from line-
scanning analysis as shown in A
as well as heart rate (HR) and
percentile fractional shortening
(FS%) measurements. Adapted
from Lu et al. [11] with
permission
HR: 545, %EF: 60.59, %FS: 32.17 HR: 545, %EF: 37.85, %FS: 18.18
HR: 533, %EF: 65.69, %FS:35.88 HR: 545, %EF: 26.61, %FS: 12.50
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Fig. 3 Expression and function
of PP2Cm in the heart.
a Expression of PP2Cm in the
heart illustrated by positive
Lac-Z staining in a PP2Cm
?/lacZ
heart. b Representative
echocardiogram of a wild type
and a PP2Cm KO heart before
and after 8 weeks of pressure
overload induced by TA
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tivity to calcium-induced permeability transition pore
opening even in the absence of BCAA or BCKA
treatment [11]. The molecular basis of this observation
remains unclear, but it may imply that branched-amino
acid metabolism is functionally coupled with mito-
chondrial inner membrane permeability, which has a
key role in mitochondrial calcium, respiration cou-
pling, ROS, and cellular viability.
Perspectives
Branched-chain amino acids are important nutrient mole-
cules with a potent signaling effect. Free BCAAs and their
catabolic intermediates, BCKAs, are tightly maintained in
animals by a highly regulated catabolic pathway. Defects
in catabolism of BCAAs cause maple syrup urine disease,
one of the most common metabolic disorders in the human
population.
Although most clinical features of maple syrup urine
disease are neurologic, our recent ﬁndings from cellular
studies and animal models suggest that missing a key
regulator in the catabolism of BCAAs also can cause a
signiﬁcant impairment in cardiac function (Fig. 4). The
implication of this observation remains to be further
established. However, a recent study based on metabolic
proﬁling of peripheral blood has demonstrated a link
between abnormal metabolism of BCAAs and coronary
diseases [21]. As the complete molecular components of
BCAA catabolic pathways are being discovered, better
diagnosis will be available to identify patients with non-
classic, intermediate, or inducible maple syrup urine dis-
ease based on sequencing evidence. The insights learned
from our study argue strongly for a better understanding of
the role that the catabolism of BCAAs plays in the heart
and its potential impact on cardiac pathology in addition to
its damage to the central nervous system.
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